Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Reactivation of M. tuberculosis infection in trans-membrane tumour necrosis factor mice.

Dambuza I, Keeton R, Allie N, Hsu NJ, Randall P, Sebesho B, Fick L, Quesniaux VJ, Jacobs M.

PLoS One. 2011;6(11):e25121. doi: 10.1371/journal.pone.0025121. Epub 2011 Nov 21.

2.

Mediators of oligodendrocyte differentiation during remyelination.

Patel JR, Klein RS.

FEBS Lett. 2011 Dec 1;585(23):3730-7. doi: 10.1016/j.febslet.2011.04.037. Epub 2011 Apr 29. Review.

3.

Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy.

Bolon B, Stolina M, King C, Middleton S, Gasser J, Zack D, Feige U.

J Biomed Biotechnol. 2011;2011:569068. doi: 10.1155/2011/569068. Epub 2010 Dec 28. Review.

4.

Interleukin-17 regulation: an attractive therapeutic approach for asthma.

Park SJ, Lee YC.

Respir Res. 2010 Jun 16;11:78. doi: 10.1186/1465-9921-11-78. Review.

5.

Cells of the synovium in rheumatoid arthritis. Chondrocytes.

Otero M, Goldring MB.

Arthritis Res Ther. 2007;9(5):220. Review. Erratum in: Arthritis Res Ther. 2008;10(1):401.

6.

Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif.

Flick MJ, LaJeunesse CM, Talmage KE, Witte DP, Palumbo JS, Pinkerton MD, Thornton S, Degen JL.

J Clin Invest. 2007 Nov;117(11):3224-35.

7.

TNF-induced structural joint damage is mediated by IL-1.

Zwerina J, Redlich K, Polzer K, Joosten L, Krönke G, Distler J, Hess A, Pundt N, Pap T, Hoffmann O, Gasser J, Scheinecker C, Smolen JS, van den Berg W, Schett G.

Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11742-7. Epub 2007 Jul 3.

8.
9.

Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients?

van de Loo FA, Smeets RL, van den Berg WB.

Arthritis Res Ther. 2004;6(5):183-96. Epub 2004 Jul 29. Review.

10.

Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice.

Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, Kanai C, Moriizumi E, Nomura T, Nakamura T, Sakaguchi S.

J Clin Invest. 2004 Aug;114(4):582-8.

11.

Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols.

Douni E, Sfikakis PP, Haralambous S, Fernandes P, Kollias G.

Arthritis Res Ther. 2004;6(1):R65-R72. Epub 2003 Nov 7.

12.

Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice.

Shealy DJ, Wooley PH, Emmell E, Volk A, Rosenberg A, Treacy G, Wagner CL, Mayton L, Griswold DE, Song XY.

Arthritis Res. 2002;4(5):R7. Epub 2002 Jun 28.

13.

Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis.

Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, Gravallese E, Mathis D, Benoist C.

J Exp Med. 2002 Jul 1;196(1):77-85.

14.
15.

A follow-up to "Anti-cytokine therapy in chronic destructive arthritis" by Wim B van den Berg.

Brennan FM.

Arthritis Res. 2001;3(4):211-3; discussion 214-5. Epub 2001 Apr 24.

16.

Macrophage- and neutrophil-dominant arthritis in human IL-1 alpha transgenic mice.

Niki Y, Yamada H, Seki S, Kikuchi T, Takaishi H, Toyama Y, Fujikawa K, Tada N.

J Clin Invest. 2001 May;107(9):1127-35.

17.

Anti-cytokine therapy in chronic destructive arthritis.

van den Berg WB.

Arthritis Res. 2001;3(1):18-26. Epub 2000 Nov 10. Review.

18.

Macrophages in rheumatoid arthritis.

Kinne RW, Bräuer R, Stuhlmüller B, Palombo-Kinne E, Burmester GR.

Arthritis Res. 2000;2(3):189-202. Epub 2000 Apr 12. Review.

19.

Arguments for interleukin 1 as a target in chronic arthritis.

van den Berg WB.

Ann Rheum Dis. 2000 Nov;59 Suppl 1:i81-4. Review.

20.

Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha.

Williams RO, Feldmann M, Maini RN.

Ann Rheum Dis. 2000 Nov;59 Suppl 1:i75-80. Review. No abstract available.

Supplemental Content

Support Center